BioSpace News Archive

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced completion of enrollment in ROSELLA, a pivotal Phase 3 trial of its proprietary selective cortisol modulator relacorilant combined with nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

C4 Therapeutics, Inc. presented a poster today at the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighting new preclinical data for CFT1946 across multiple models of BRAF V600X mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), additional BRAF inhibitor.

Mesa Laboratories, Inc. announced the closing of its Amended and Restated Credit Agreement, which provides up to $200 million of senior secured debt through a syndicate of banks led by JPMORGAN CHASE BANK, N.A.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced a regulatory update for SPN-830.

TScan Therapeutics, Inc. today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer.

Gritstone bio, Inc. today announced that management will be participating in the following investor and scientific conferences.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib).

Stealth BioTherapeutics today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing its New Drug Application (“NDA”) for elamipretide for the treatment of Barth syndrome.

AffyImmune Therapeutics, Inc today announced the formation of a Clinical and Regulatory Advisory Board (CRAB), comprised of distinguished experts in cancer research, immunology, and CAR T therapy.

Natera, Inc. today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA (dd-cfDNA) test to detect rejection in adult and pediatric heart transplant recipients.